(Q39558094)

13 September 2017

Zoledronic acid enhances Vδ2 T-lymphocyte antitumor response to human glioma cell lines (English)

1 reference

13 September 2017

1 reference

E Cimini

1

1 reference

13 September 2017

P Piacentini

2

1 reference

13 September 2017

A Sacchi

3

1 reference

13 September 2017

C Gioia

4

1 reference

13 September 2017

S Leone

5

1 reference

13 September 2017

G M Lauro

6

1 reference

13 September 2017

F Martini

7

1 reference

13 September 2017

C Agrati

8

1 reference

13 September 2017

1 January 2011

1 reference

International Journal of Immunopathology and Pharmacology

13 September 2017

1 reference

13 September 2017

24

1 reference

13 September 2017

1

1 reference

13 September 2017

139-148

1 reference

The WHO classification of tumors of the nervous system

13 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Brain tumor survival: results from the National Cancer Data Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Chemotherapy for brain tumors--a new beginning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

The plasticity of gamma delta T cells: innate immunity, antigen presentation and new immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Antiviral reactivities of gammadelta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

V gamma 9V delta 2 T cell response to colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Antitumor effects of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Gammadelta T cells for immune therapy of patients with lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Current and future strategies for the treatment of malignant brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Systemic T cell adoptive immunotherapy of malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to gammadelta T-cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463201102400116

10.1177/039463201102400116

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference